← 返回首页
大洋洲 · 综合新闻 · The Mercury

Neurizon advances Regimen I into treatment extension alongside $3.7m R&D drawdown

来源:The Mercury · 澳大利亚 10 小时前
Neurizon advances Regimen I into treatment extension alongside $3.7m R&D drawdown
The Mercury

详细摘要

The first participant in Regimen I of Neurizon Therapeutics’ Phase 2/3 ALS Platform Trial has completed the 36-week randomised controlled trial (RCT) phase and transitioned into…

在 The Mercury 阅读全文 登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要,全文请在出版方网站阅读。 (www.themercury.com.au)

推荐阅读